Immix Biopharma Inc (IMMX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $657.09M
Last updated: Nov 17, 2026 at 11:05 AM ET
Immix Biopharma Inc (IMMX) Stock Forecast
Analysts expect Immix Biopharma (IMMX) to earn -$0.72 per share in the fiscal year ending Dec 31, 2026. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.57, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 42.9% |
| Buy | 4 | 57.1% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.72
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.95
- EPS consensus, revenue $27.86M
- Next report
- Mar 23, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.72 | -$0.80 to -$0.51 | 8 | N/A | N/A | 5 |
| Dec 31, 2027 | -$0.95 | -$1.45 to -$0.20 | 8 | $27.86M | N/A | 6 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.21 | -$0.25 to -$0.18 | 9 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.71.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.72 | -$0.72 | -$0.71 | -$0.75 | -$0.71 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.95 | -$0.95 | -$0.85 | -$0.91 | -$0.84 | N/A |
Frequently Asked Questions About IMMX
What is the IMMX stock forecast?
Consensus analyst estimates put Immix Biopharma's EPS at -$0.72 for the fiscal year ending Dec 31, 2026. The consensus rating from 7 analysts is Buy.
How do analysts rate IMMX stock?
Of 7 analysts covering Immix Biopharma, 3 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IMMX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.72, with estimates from -$0.80 to -$0.51 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.95, with estimates from -$1.45 to -$0.20 from 8 analysts.
What revenue do analysts expect from Immix Biopharma next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $27.86M.
How many analysts cover IMMX?
7 analysts rate Immix Biopharma stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IMMX pages: Overview, Earnings, Forecast, Financials, Competitors